PMID- 33955004
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1745-4514 (Electronic)
IS  - 0145-8884 (Linking)
VI  - 45
IP  - 6
DP  - 2021 Jun
TI  - Subclinical hypothyroidism contributes to poor glycemic control in patients with 
      type 2 diabetes mellitus, and ellagic acid attenuates methimazole-induced 
      abnormal glucose metabolism in mice model.
PG  - e13753
LID - 10.1111/jfbc.13753 [doi]
AB  - Subclinical hypothyroidism (SCH) as mild thyroid disorder or comorbidity in 
      patients with endocrine disorders is closely related with insulin resistance (IR) 
      and poor glycemic control. The present study attempted to investigate the effect 
      of SCH on IR and glycemic control in patients with type 2 diabetes mellitus 
      (T2DM). In addition, the effects of ellagic acid (EA) on SCH C57BL/6J and db/db 
      mice were also investigated to explore potential therapeutic drug against 
      SCH-induced abnormal glucose metabolism. T2DM patients were recruited in our 
      study and categorized into two groups according to thyroid stimulating hormone 
      (TSH) value: T2DM without SCH group (TSH </=4 muIU/ml; n = 30) and T2DM with SCH 
      group (TSH >4muIU/ml; n = 60). Methimazole (MMI; 0.08 mg kg(-1)  day(-1) ) was 
      intragastrically administrated for 12 weeks to establish SCH in C57BL/6J and 
      db/db mice. Compared with T2DM patients without SCH, poor glycemic and 
      cholesterol control were emerged in T2DM patients with SCH and that were 
      prominent in patients with TSH more than 10 muIU/ml. In addition, a significant 
      positive correlation between serum TSH and fasting plasma-glucose (FPG), total 
      cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or glycated 
      hemoglobin (HbA1c) was observed in T2DM patients with SCH. Moreover, abnormal 
      glucose metabolism in C57BL/6J and db/db mice with SCH has been attenuated by EA 
      administration. Our findings provided data regarding the positive correlation 
      between high TSH level with poor glycemic control in T2DM patients with SCH. EA 
      might be a supportive strategy for preventing SCH-induced abnormal glucose 
      metabolism. PRACTICAL APPLICATIONS: Subclinical hypothyroidism (SCH) is a 
      potential risk factor associated with abnormal glucose metabolism in patients 
      with type 2 diabetes mellitus (T2DM). A clinical theory of a positive correlation 
      between high TSH level and poor glycemic control was validated in type 2 diabetes 
      mellitus patients and mouse models. Ellagic acid (EA) might be a supportive 
      strategy for preventing SCH-induced abnormal glucose metabolism that provided a 
      treatment option in T2DM patients with subclinical hypothyroidism in clinical 
      practice.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Liu, Ye
AU  - Liu Y
AUID- ORCID: 0000-0002-5100-4920
AD  - Department of Endocrinology, ShanXi Medical University, Taiyuan, China.
FAU - Li, Xing
AU  - Li X
AD  - Department of Endocrinology, ShanXi Medical University, Taiyuan, China.
FAU - Zhu, Yikun
AU  - Zhu Y
AD  - Department of Endocrinology, ShanXi Medical University, Taiyuan, China.
FAU - Liu, Jiong
AU  - Liu J
AD  - Department of Nuclear Medicine, ShanXi Medical University, Taiyuan, China.
FAU - Liu, Sunjun
AU  - Liu S
AD  - Department of Endocrinology, ShanXi Medical University, Taiyuan, China.
LA  - eng
PT  - Journal Article
DEP - 20210505
PL  - United States
TA  - J Food Biochem
JT  - Journal of food biochemistry
JID - 7706045
RN  - 19YRN3ZS9P (Ellagic Acid)
RN  - 554Z48XN5E (Methimazole)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Ellagic Acid/pharmacology
MH  - Glucose
MH  - Glycemic Control
MH  - Humans
MH  - *Hypothyroidism/chemically induced/drug therapy
MH  - Methimazole
MH  - Mice
MH  - Mice, Inbred C57BL
OTO - NOTNLM
OT  - ellagic acid
OT  - glucose metabolism disorders
OT  - hypothyroidism
OT  - insulin resistance
OT  - type 2 diabetes mellitus
EDAT- 2021/05/07 06:00
MHDA- 2021/07/10 06:00
CRDT- 2021/05/06 07:21
PHST- 2021/04/14 00:00 [revised]
PHST- 2021/03/15 00:00 [received]
PHST- 2021/04/18 00:00 [accepted]
PHST- 2021/05/07 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2021/05/06 07:21 [entrez]
AID - 10.1111/jfbc.13753 [doi]
PST - ppublish
SO  - J Food Biochem. 2021 Jun;45(6):e13753. doi: 10.1111/jfbc.13753. Epub 2021 May 5.